|
|
Prepublished online as a Blood First Edition Paper on May 22, 2003; DOI 10.1182/blood-2003-03-0676.
 Previous Article | Table of Contents | Next Article 
Blood, 15 September 2003, Vol. 102, No. 6, pp. 2240-2242
NEOPLASIA
Brief report
Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro
Leopold Oehler,
Eva Jaeger,
Alexander Eser,
Christian Sillaber,
Heinz Gisslinger, and
Klaus Geissler
From the Division of Hematology, Department of Internal Medicine I, University of Vienna; and the Fifth Medical Department-Oncology, Hospital Lainz, Vienna, Austria.
The overproduction of red blood cells in patients with polycythemia vera (PV) is reflected in vitro by the formation of erythroid burst-forming units (BFU-Es) in the absence of exogenous erythropoietin. In contrast to other myeloproliferative disorders, the molecular mechanism of PV is unknown and no specific chromosomal abnormality has been described. We speculated that imatinib mesylate may reverse the pathological overproduction of red cells by inhibition of autonomous erythropoiesis. In the present study, imatinib mesylate was found to either block or strongly inhibit autonomous BFU-E formation in vitro in all patients tested. Moreover, autonomous BFU-E growth was also markedly reduced by exposure of PV cells to imatinib mesylate prior to cultivation in semisolid medium. The profound effect of imatinib mesylate on autonomous erythropoiesis suggests the involvement of an as yet unidentified kinase in the pathogenesis of PV and should provide the rationale for a forthcoming clinical trial.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
Imatinib mesylate in polycythemia vera
- Jerry L. Spivak, Richard T. Silver, Leopold Oehler, and Klaus Geissler
Blood 2004 103: 3241-3242.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
Z. Li, M. Xu, S. Xing, W. T. Ho, T. Ishii, Q. Li, X. Fu, and Z. J. Zhao
Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth
J. Biol. Chem.,
February 9, 2007;
282(6):
3428 - 3432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Larghero, N. Gervais, B. Cassinat, J.-D. Rain, M.-H. Schlageter, R. A. Padua, C. Chomienne, and P. Rousselot
Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells
Blood,
May 1, 2005;
105(9):
3743 - 3745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Vainchenker and S. N. Constantinescu
A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases
Hematology,
January 1, 2005;
2005(1):
195 - 200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hasselbalch
Imatinib Mesylate in Polycythemia Vera. A Heterogeneous Response Pattern but a Consistent Reduction in Phlebotomy Requirements.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
4747 - 4747.
[Abstract]
|
|
|
|
|
|
|
A. Pardanani and A. Tefferi
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
Blood,
October 1, 2004;
104(7):
1931 - 1939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Spivak, R. T. Silver, L. Oehler, and K. Geissler
Imatinib mesylate in polycythemia vera
Blood,
April 15, 2004;
103(8):
3241 - 3242.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Bartolovic, S. Balabanov, U. Hartmann, M. Komor, A. M. Boehmler, H.-J. Buhring, R. Mohle, D. Hoelzer, L. Kanz, W.-K. Hofmann, et al.
Inhibitory effect of imatinib on normal progenitor cells in vitro
Blood,
January 15, 2004;
103(2):
523 - 529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
